Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

被引：4557

作者：

Lacey, DL

Timms, E

Tan, HL

Kelley, MJ

Dunstan, CR

Burgess, T

Elliott, R

Colombero, A

Elliott, G

Scully, S

Hsu, H

Sullivan, J

Hawkins, N

Davy, E

Capparelli, C

Eli, A

Qian, YX

Kaufman, S

Sarosi, I

Shalhoub, V

Senaldi, G

Guo, J

Delaney, J

Boyle, WJ

机构：

[1] Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA

[2] Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Dept Prot Chem, Thousand Oaks, CA 91320 USA

[4] Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, Dept Bacterial Express, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, Dept Proc Sci, Thousand Oaks, CA 91320 USA

来源：

CELL | 1998年 / 93卷 / 02期

关键词：

D O I：

10.1016/S0092-8674(00)81569-X

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes that typify osteoclast development. OPGL directly activates isolated mature osteoclasts in vitro, and shortterm administration into normal adult mice results in osteoclast activation associated with systemic hypercalcemia. These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development.

引用

页码：165 / 176

页数：12

共 24 条

[1] DIFFERENTIATION-INDUCING FACTOR PURIFIED FROM CONDITIONED MEDIUM OF MITOGEN-TREATED SPLEEN-CELL CULTURES STIMULATES BONE-RESORPTION
ABE, E
TANAKA, H
ISHIMI, Y
MIYAURA, C
HAYASHI, T
NAGASAWA, H
TOMIDA, M
YAMAGUCHI, Y
HOZUMI, M
SUDA, T
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (16) : 5958 - 5962
[2] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
Anderson, DM
Maraskovsky, E
Billingsley, WL
Dougall, WC
Tometsko, ME
Roux, ER
Teepe, MC
DuBose, RF
Cosman, D
Galibert, L
[J]. NATURE, 1997, 390 (6656) : 175 - 179
[3] EFFECT OF PH ON BONE-RESORPTION BY RAT OSTEOCLASTS INVITRO
ARNETT, TR
DEMPSTER, DW
[J]. ENDOCRINOLOGY, 1986, 119 (01) : 119 - 124
[4] CRYSTAL-STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX - IMPLICATIONS FOR TNF RECEPTOR ACTIVATION
BANNER, DW
DARCY, A
JANES, W
GENTZ, R
SCHOENFELD, HJ
BROGER, C
LOETSCHER, H
LESSLAUER, W
[J]. CELL, 1993, 73 (03) : 431 - 445
[5] B61 IS A LIGAND FOR THE ECK RECEPTOR PROTEIN-TYROSINE KINASE
BARTLEY, TD
HUNT, RW
WELCHER, AA
BOYLE, WJ
PARKER, VP
LINDBERG, RA
LU, HS
COLOMBERO, AM
ELLIOTT, RL
GUTHRIE, BA
HOLST, PL
SKRINE, JD
TOSO, RJ
ZHANG, M
FERNANDEZ, E
TRAIL, G
VARNUM, B
YARDEN, Y
HUNTER, T
FOX, GM
[J]. NATURE, 1994, 368 (6471) : 558 - 560
[6] MAPPING THE DOMAIN(S) CRITICAL FOR THE BINDING OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA TO ITS 2 RECEPTORS
CHEN, PCH
DUBOIS, GC
CHEN, MJ
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (06) : 2874 - 2878
[7] Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
Chinnaiyan, AM
ORourke, K
Yu, GL
Lyons, RH
Garg, M
Duan, DR
Xing, L
Gentz, R
Ni, J
Dixit, VM
[J]. SCIENCE, 1996, 274 (5289) : 990 - 992
[8] EVANS RA, 1979, MINER ELECTROL METAB, V2, P179
[9] OSTEOCLAST RESORPTION - STIMULATING ACTIVITY IS ASSOCIATED WITH THE OSTEOBLAST CELL-SURFACE AND OR THE EXTRACELLULAR-MATRIX
FULLER, K
GALLAGHER, AC
CHAMBERS, TJ
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (01) : 67 - 73
[10] OSTEOCLAST RECRUITING ACTIVITY IN BONE-MATRIX
HENTUNEN, TA
CUNNINGHAM, NS
VUOLTEENAHO, O
REDDI, AH
VAANANEN, HK
[J]. BONE AND MINERAL, 1994, 25 (03): : 183 - 198

← 1 2 3 →